Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Lancet Psychiatry. 2016 Mar 16;3(5):425–435. doi: 10.1016/S2215-0366(16)00012-2

Figure 2. Impairment in cognition before and after treatment in patients, compared across clinical outcome groups.

Figure 2

Normalised performance scores shown as group mean (SE) in the domains of (A) attention and response inhibition, (B) visuospatial navigation and cognitive flexibility, (C) verbal memory and working memory, and (D) psychomotor function, decision speed, and information processing. MDD-remit=patients with major depressive disorder whose clinical symptoms remitted (defined by HRSD-17). HRSD-17=17-item Hamilton Rating Scale for Depression. MDD-non-remit=patients with depression whose clinical symptoms did not remit. NS=non-significant. *Denotes significance of repeated measures ANOVA main effect of group, for the comparison of MDD-remit patients vs healthy controls. †Denotes significance of post-hoc t test between indicated groups at week 8.